Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen <it>Plasmodium falciparum</it> FVO merozoite surface protein-1 (MSP1₄₂) administered intramuscularly with adjuvant system AS01

<p>Abstract</p> <p>Background</p> <p>The development of an asexual blood stage vaccine against <it>Plasmodium falciparum</it> malaria based on the major merozoite surface protein-1 (MSP1) antigen is founded on the protective efficacy observed in preclinical studies and induction of invasion and grow...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Otsyula Nekoye, Angov Evelina, Bergmann-Leitner Elke, Koech Margaret, Khan Farhat, Bennett Jason, Otieno Lucas, Cummings James, Andagalu Ben, Tosh Donna, Waitumbi John, Richie Nancy, Shi Meng, Miller Lori, Otieno Walter, Otieno Godfrey Allan, Ware Lisa, House Brent, Godeaux Olivier, Dubois Marie-Claude, Ogutu Bernhards, Ballou W Ripley, Soisson Lorraine, Diggs Carter, Cohen Joe, Polhemus Mark, Heppner D Gray, Ockenhouse Christian F, Spring Michele D
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2013-01-01
coleção:	Malaria Journal
Assuntos:	Malaria Vaccine Merozoite surface protein-1 <it>Plasmodium</it>
Acesso em linha:	http://www.malariajournal.com/content/12/1/29
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!